By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cervical Cancer Vaccine Yields Long Term Positive Effects
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Cervical Cancer Vaccine Yields Long Term Positive Effects
Public HealthTechnology

Cervical Cancer Vaccine Yields Long Term Positive Effects

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

Inovio Pharmaceuticals (AMEX:INO) reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer cause

Inovio Pharmaceuticals (AMEX:INO) reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.

In a follow-on study, the company’s SynCon DNA vaccine showed T-cell immune responses of up to over two years in 7 of 8 patients tested, following a fourth vaccination of VGX-3100. The vaccine was delivered using intramuscular electroportation.

The company said the data further highlights the viability of using multiple booster vaccinations with a DNA vaccine, which  are designed to provide broad cross-strain protection against a number of strains of pathogens.

More Read

eHealth
Electronic Health Records: Still Not Good Enough (Part 2)
What Are the Limitations of Big Data in Healthcare?
Person-Centered HealthCare: At-Home Care is Key
How Smart Doctors Protect and Encrypt Their Patients Information
Healthcare Security: HIPAA Standards and The Challenges of Securing Mobile Data

Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 oncogenes common to specific HPV types, which are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The goal is to stimulate a T-cell immune response strong enough to reject these infected or transformed cells from the body.

“Achieving long-lasting immune responses exceeding two years is exceptional,” said Inovio president and CEO, Dr. J. Joseph Kim.

“In general, the durability of these T cell responses places Inovio’s DNA vaccine technology on par with live virus vaccines, but without their various safety and other issues, and substantially exceeds current data from alternative non-replicating vaccine technologies.

“Furthermore, being able to use multiple vaccinations without safety concerns or unwanted immune responses is a notable advantage of Inovio’s DNA vaccine technology.”

Currently, there is no therapeutic live virus or non-replicating vaccine for cervical dysplasias, which are pre-cancerous lesions, and cancers in the market.

Inovio’s original phase one trial treated 18 women who had previously been diagnosed with and surgically treated for a pre-malignant lesion that may lead to cervical cancer, with a three-vaccination regimen of its VGX-3100.

In a longer-term analysis of T cell responses, at nine or more months after the initial vaccination, of 13 initially responding patients, 12, or 92%, had maintained significant T cell responses nine to 19 months after their first vaccination.

The company then decided to initiate the latest follow-on study, with the intent to assess the safety and immune responses following a fourth vaccination. Of the original 18 subjects, 11 T-cell responders and two non-responders agreed to participate, for a total of 13. Of the 13, only 8 have been analyzed thus far, Inovio said.

Based on the promising results, the vaccine developer is now recruiting for its phase two study, which is designed to enroll 148 patients with pre-cancerous cervical lesions, at around 25 centres in the US, Korea, South Africa, Australia and Canada.–Deborah Sterescu

 

TAGGED:cervical cancerHPVInoviavaccines
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Top 10 Health Technology Hazards For 2013

November 7, 2012
Public Health

2012: The Year in HealthCare Charts

January 8, 2013
health benefits of gene targeting research
Medical EducationMedical InnovationsPolicy & LawTechnology

Breakthroughs in Gene Targeting in Mouse Can Help Humans

October 28, 2022

Osteoarthritis and Obesity Can Shave 3.5 Years of Healthy Life

March 29, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?